317 related articles for article (PubMed ID: 15909786)
1. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.
Mystakidou K; Katsouda E; Parpa E; Tsiatas ML; Vlahos L
Am J Hosp Palliat Care; 2005; 22(3):228-32. PubMed ID: 15909786
[TBL] [Abstract][Full Text] [Related]
2. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.
Mystakidou K; Katsouda E; Parpa E; Tsiatas ML; Vlahos L
J Opioid Manag; 2005; 1(1):36-40. PubMed ID: 17315410
[TBL] [Abstract][Full Text] [Related]
3. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
[TBL] [Abstract][Full Text] [Related]
4. Fentanyl buccal tablet.
Messina J; Darwish M; Fine PG
Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
[TBL] [Abstract][Full Text] [Related]
5. Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology.
Mystakidou K; Tsilika E; Tsiatas M; Vlahos L
Int J Nanomedicine; 2007; 2(1):49-54. PubMed ID: 17722512
[TBL] [Abstract][Full Text] [Related]
6. Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics.
Mystakidou K; Katsouda E; Parpa E; Vlahos L; Tsiatas ML
Drug Deliv; 2006; 13(4):269-76. PubMed ID: 16766468
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and clinical differences among transmucosal fentanyl formulations for the treatment of breakthrough cancer pain: a review article.
Corli O; Roberto A
Minerva Anestesiol; 2014 Oct; 80(10):1123-34. PubMed ID: 24346227
[TBL] [Abstract][Full Text] [Related]
8. Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review.
Gordon DB
Oncol Nurs Forum; 2006 Nov; 33(2):257-64. PubMed ID: 16518441
[TBL] [Abstract][Full Text] [Related]
9. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).
Coluzzi PH; Schwartzberg L; Conroy JD; Charapata S; Gay M; Busch MA; Chavez J; Ashley J; Lebo D; McCracken M; Portenoy RK
Pain; 2001 Mar; 91(1-2):123-30. PubMed ID: 11240084
[TBL] [Abstract][Full Text] [Related]
10. The role of oral transmucosal fetanyl citrate in the management of breakthrough cancer pain.
Rees E
Int J Palliat Nurs; 2002 Jun; 8(6):304-8. PubMed ID: 12131825
[TBL] [Abstract][Full Text] [Related]
11. Opioids for the management of breakthrough pain in cancer patients.
Zeppetella G; Davies AN
Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
[TBL] [Abstract][Full Text] [Related]
12. [Breakthrough pain frequency in cancer patients and the efficiency of oral transmucosal fentanyl citrate].
Bilen A; Ali A; Baturay F; Altan A
Agri; 2010 Jul; 22(3):103-8. PubMed ID: 20865581
[TBL] [Abstract][Full Text] [Related]
13. Managing breakthrough pain: a clinical review with three case studies using oral transmucosal fentanyl citrate.
Rhiner M; Palos G; Termini M
Clin J Oncol Nurs; 2004 Oct; 8(5):507-12. PubMed ID: 15515284
[TBL] [Abstract][Full Text] [Related]
14. Oral transmucosal fentanyl citrate--OTFC (ACTIQ) #103.
Gordon D; Schroeder M
J Palliat Med; 2008 May; 11(4):633-4. PubMed ID: 18454617
[No Abstract] [Full Text] [Related]
15. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
Elsner F; Zeppetella G; Porta-Sales J; Tagarro I
Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159
[TBL] [Abstract][Full Text] [Related]
16. Treating cancer-related breakthrough pain: the oral transmucosal route.
Laverty D
Int J Palliat Nurs; 2007 Jul; 13(7):326-31. PubMed ID: 17851376
[TBL] [Abstract][Full Text] [Related]
17. Fentanyl nasal spray for the treatment of cancer pain.
Mystakidou K; Panagiotou I; Gouliamos A
Expert Opin Pharmacother; 2011 Jul; 12(10):1653-9. PubMed ID: 21609189
[TBL] [Abstract][Full Text] [Related]
18. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study.
Hanks GW; Nugent M; Higgs CM; Busch MA;
Palliat Med; 2004 Dec; 18(8):698-704. PubMed ID: 15623166
[TBL] [Abstract][Full Text] [Related]
19. Fentanyl effervescent buccal tablets: new formulation. For cancer patients with breakthrough pain: a second buccal formulation with minimal evaluation.
Prescrire Int; 2009 Oct; 18(103):205. PubMed ID: 19882786
[TBL] [Abstract][Full Text] [Related]
20. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.
Mercadante S
Expert Opin Pharmacother; 2012 Apr; 13(6):873-8. PubMed ID: 22424558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
